Wall Street equity research analysts covering Protara Therapeutics Inc. (TARA) maintain a consensus twelve-month average price target of approximately $26.25 per share, with individual forecasts ranging from a low of $20 up to a high of $30. These optimistic projections reflect high institutional confidence in the company's proprietary pipeline developments and orphan drug clinical programs, representing a significant potential upside relative to its current trading valuation.